SLC5A2 and chronic kidney disease: Recently, sodium glucose co-transporter 2 (SGLT2) inhibitors have been shown to have clinical benefits in patients with type 2 diabetes at high cardiovascular (CV) risk, chronic renal insufficiency, or HF.